Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28268476 | 0.86 | EPHX2 (0.65) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28266759 | 0.86 | RORC (0.61) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28353018 | 0.85 | RORC (0.66) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28909371 | 0.85 | RORC (0.62) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL23632544 | 0.83 | RORC (0.61) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28349854 | 0.83 | CA2 (0.64) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL23632292 | 0.83 | CA1 (0.72) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL29488705 | 0.83 | RORC (0.71) | RORCCA2CA1ALDH1A1 | |
| SCHEMBL28266785 | 0.82 | RORC (0.60) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28266766 | 0.82 | RORC (0.57) | RORCCA2CA1EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513021-B | ROR gamma antagonist and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-112513021-A | ROR gamma antagonist and application thereof in medicine | 广东东阳光药业有限公司 | 2021-03-16 | — | — | CN | disclosed |